{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:33:15Z","timestamp":1767713595130,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T00:00:00Z","timestamp":1673740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022795","name":"Hamilton Health Sciences Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ctro.2023.100583","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T11:58:30Z","timestamp":1674043110000},"page":"100583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer"],"prefix":"10.1016","volume":"39","author":[{"given":"Aruz","family":"Mesci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0472-4615","authenticated-orcid":false,"given":"Elham","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-0605","authenticated-orcid":false,"given":"Amr","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1617-3833","authenticated-orcid":false,"given":"Mohammad","family":"Gouran-Savadkoohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia","family":"Evelyn Tsakiridis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga-Demetra","family":"Biziotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6372-1604","authenticated-orcid":false,"given":"Tom","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monalisa","family":"Sur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory R.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6851-0857","authenticated-orcid":false,"given":"Stanley","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Zukotynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros","family":"Tsakiridis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctro.2023.100583_b0005","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ijrobp.2019.03.014","article-title":"A Multicenter prospective clinical trial of (68)Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: oligometastatic rate and distribution compared with standard imaging","volume":"104","author":"McCarthy","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2023.100583_b0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1148\/rg.2018170108","article-title":"Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls","volume":"38","author":"Hofman","year":"2018","journal-title":"Radiographics"},{"issue":"10231","key":"10.1016\/j.ctro.2023.100583_b0015","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2023.100583_b0020","article-title":"Evaluation of 18F-DCFPyL PSMA PET\/CT for prostate cancer: a meta-analysis","volume":"10","author":"Pan","year":"2020","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2023.100583_b0025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","article-title":"Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer","volume":"17","author":"Szabo","year":"2015","journal-title":"Mol Imaging Biol"},{"issue":"11","key":"10.1016\/j.ctro.2023.100583_b0030","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2967\/jnumed.119.226381","article-title":"A prospective study on 18F-DCFPyL PSMA PET\/CT Imaging in biochemical recurrence of prostate cancer","volume":"60","author":"Rousseau","year":"2019","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.ctro.2023.100583_b0035","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctro.2023.100583_b0040","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1471-4159.2000.0750443.x","article-title":"N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system","volume":"75","author":"Neale","year":"2000","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.ctro.2023.100583_b0045","doi-asserted-by":"crossref","first-page":"657","DOI":"10.33549\/physiolres.933932","article-title":"Dissecting the role of Folr1 and Folh1 genes in the pathogenesis of metabolic syndrome in spontaneously hypertensive rats","volume":"67","author":"Silhavy","year":"2018","journal-title":"Physiol Res"},{"issue":"7","key":"10.1016\/j.ctro.2023.100583_b0050","first-page":"1807","article-title":"Expression of the prostate-specific membrane antigen","volume":"54","author":"Israeli","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctro.2023.100583_b0055","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ctro.2023.100583_b0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/ERC-18-0226","article-title":"Neuroendocrine differentiation of prostate cancer leads to PSMA suppression","volume":"26","author":"Bakht","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"14","key":"10.1016\/j.ctro.2023.100583_b0065","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.7150\/thno.44584","article-title":"Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with (68)Ga-PSMA-11-PET","volume":"10","author":"Ferraro","year":"2020","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.ctro.2023.100583_b0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12253-008-9104-2","article-title":"Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis","volume":"15","author":"Mannweiler","year":"2009","journal-title":"Pathol Oncol Res"},{"issue":"4","key":"10.1016\/j.ctro.2023.100583_b0075","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00066-017-1239-1","article-title":"Oligometastases in prostate cancer: metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT","volume":"194","author":"Baumann","year":"2018","journal-title":"Strahlenther Onkol"},{"issue":"23","key":"10.1016\/j.ctro.2023.100583_b0080","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.1106383108","article-title":"Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen","volume":"108","author":"Evans","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.ctro.2023.100583_b0085","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00432-021-03583-w","article-title":"Antihormone treatment differentially regulates PSA secretion, PSMA expression and 68Ga\u2013PSMA uptake in LNCaP cells","volume":"147","author":"Mathy","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2023.100583_b0090","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-015-0145-8","article-title":"Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy","volume":"5","author":"Meller","year":"2015","journal-title":"EJNMMI Res"},{"issue":"14","key":"10.1016\/j.ctro.2023.100583_b0095","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-21-4531","article-title":"Prostate-Specific membrane antigen expression and response to DNA damaging agents in prostate cancer","volume":"28","author":"Sheehan","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctro.2023.100583_b0100","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.18632\/oncotarget.13576","article-title":"Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer","volume":"8","author":"Ghiam","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.ctro.2023.100583_b0105","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/bjc.2013.187","article-title":"Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK","volume":"108","author":"Storozhuk","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctro.2023.100583_b0110","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cmet.2018.08.020","article-title":"Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma","volume":"29","author":"Lally","year":"2019","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.ctro.2023.100583_b0115","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"11","key":"10.1016\/j.ctro.2023.100583_b0120","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/00000478-200111000-00007","article-title":"P504S: a new molecular marker for the detection of prostate carcinoma","volume":"25","author":"Jiang","year":"2001","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ctro.2023.100583_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2004.12.003","article-title":"Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3","volume":"435","author":"Laidler","year":"2005","journal-title":"Arch Biochem Biophys"},{"issue":"6","key":"10.1016\/j.ctro.2023.100583_b0130","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1365-2605.2009.01030.x","article-title":"Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation","volume":"33","author":"Marchiani","year":"2010","journal-title":"Int J Androl"},{"issue":"2","key":"10.1016\/j.ctro.2023.100583_b0135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1097-0320(19980601)32:2<71::AID-CYTO1>3.0.CO;2-H","article-title":"Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis","volume":"32","author":"Juan","year":"1998","journal-title":"Cytometry"},{"issue":"4","key":"10.1016\/j.ctro.2023.100583_b0140","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","article-title":"Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer","volume":"17","author":"Dietlein","year":"2015","journal-title":"Mol Imaging Biol"},{"issue":"2","key":"10.1016\/j.ctro.2023.100583_b0145","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright","year":"1996","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ctro.2023.100583_b0150","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/PAI.0000000000000110","article-title":"PSMA expression is highly homogenous in primary prostate cancer","volume":"23","author":"Tsourlakis","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630823000083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630823000083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:14:05Z","timestamp":1762503245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630823000083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":30,"alternative-id":["S2405630823000083"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2023.100583","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2023.100583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100583"}}